文献速递肝病

VOX/VEL/SOF治疗失败后的耐药特征与挽救治疗疗效

Failure on voxilaprevir, velpatasvir, sofosbuvir and efficacy of rescue therapy.
PubMed 文献 · J Hepatol · 2020-11-19

欧洲耐药研究组收集40例VOX/VEL/SOF再治疗失败的HCV 1-4型患者样本,分析耐药相关替换(RAS)特征,并回顾性评估22例患者的挽救治疗疗效。失败多见于GT3a和GT1a合并肝硬化者,未发现特定RAS模式;挽救治疗持续病毒学应答(SVR)率达81%。

要点

  • VOX/VEL/SOF失败以HCV GT3a和GT1a合并肝硬化患者为主。
  • 失败后NS3、NS5A和NS5B靶区未见特定RAS模式。
  • 多靶点挽救治疗在多数患者中有效,SVR率为81%。

核心结论

  • VOX/VEL/SOF失败主要见于HCV GT3和GT1a合并肝硬化患者,且与NS3、NS5A或NS5B靶区特定RAS模式无关。
  • 多靶点挽救治疗对多数患者有效。

研究设计与样本

  • 欧洲耐药研究组收集40例HCV GT1-4患者VOX/VEL/SOF再治疗失败后的样本进行基于人群的耐药分析。
  • 对22例患者回顾性评估临床参数和挽救治疗疗效。

主要发现

  • 失败患者中GT3a占45%(18例),GT1a占28%(11例),肝硬化占70%(28例)。
  • 既往治疗包括NS3抑制剂30%、NS5A抑制剂100%和SOF 85%。
  • VOX/VEL/SOF再治疗前基线RAS数据(78%亚组)显示:除GT1a中Q80K(40%)外NS3 RAS较少,多数患者(74%)有典型NS5A RAS模式,NS5B未见S282T。
  • VOX/VEL/SOF失败后测序(98%患者)显示NS3和NS5A RAS仅有微小变化。
  • 22例挽救治疗采用格卡瑞韦/匹布他韦单用(2例)或联合SOF±利巴韦林(15例)、VOX/VEL/SOF±利巴韦林(4例)或VEL/SOF联合利巴韦林(1例),疗程12至24周;最终治疗结局的21例中17例(81%)获得SVR。

关键数值与推荐

  • VOX/VEL/SOF失败患者中GT3a占45%(18/40),GT1a占28%(11/40),肝硬化占70%(28/40)。
  • 基线NS3 RAS除GT1a Q80K(40%)外较少,典型NS5A RAS模式见于74%患者,NS5B无S282T。
  • 挽救治疗后SVR率为81%(17/21)。

临床怎么用

  • 对VOX/VEL/SOF再治疗失败的HCV GT3或GT1a肝硬化患者,可考虑多靶点挽救治疗。
  • 挽救治疗前可参考耐药检测,但NS3/NS5A/NS5B靶区RAS模式对失败预测价值有限。

局限性

  • 挽救治疗疗效仅回顾性评估22例患者,样本量有限。
  • 部分患者(2例)在治疗期间或达到SVR12前死亡,可能影响结局评估。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: There are limited data on patients with chronic HCV infection in whom combination voxilaprevir (VOX), velpatasvir (VEL), sofosbuvir (SOF) retreatment fails. Thus, we aimed to assess treatment failure and rescue treatment options in these patients. METHODS: Samples from 40 patients with HCV genotypes (GT) 1-4 in whom VOX/VEL/SOF retreatment failed were collected within the European Resistance Study Group. Population-based resistance analyses were conducted and clinical parameters and retreatment efficacies were evaluated retrospectively in 22 patients. RESULTS: Most VOX/VEL/SOF failure patients were infected with HCV GT3a (n = 18, 45%) or GT1a (n = 11, 28%) and had cirrhosis (n = 28, 70%). Previous treatments included an NS3-inhibitor (30%), an NS5A-inhibitor (100%) and SOF (85%). Baseline RAS data from a subgroup of patients before VOX/VEL/SOF retreatment (78%) showed few NS3 RASs apart from Q80K in GT1a (40%), typical NS5A RAS patterns in most patients (74%) and no S282T in NS5B. Sequencing after VOX/VEL/SOF failure was available in 98% of patients and showed only minor changes for NS3 and NS5A RASs. In 22 patients, rescue treatment was initiated with glecaprevir, pibrentasvir alone (n = 2) or with SOF±ribavirin (n = 15), VOX/VEL/SOF±ribavirin (n = 4) or VEL/SOF and ribavirin (n = 1) for 12 to 24 weeks. Sustained virologic response was achieved in 17/21 (81%) patients with a final treatment outcome. Of these, 2 GT3a-infected patients had virologic failure after rescue treatment with VEL/SOF or glecaprevir/pibrentasvir+SOF+ribavirin, and 2 patients with cirrhosis died during treatment or before reaching SVR12. CONCLUSIONS: VOX/VEL/SOF failure was mainly observed in HCV GT3- and GT1a-infected patients with cirrhosis and was not associated with specific RAS patterns within NS3, NS5A or NS5B target regions. Rescue treatment with multiple targeted therapies was effective in most patients. LAY SUMMARY: The advent of direct-acting antivirals has enabled the effective cure of chronic hepatitis C in most patients. However, treatment failure occurs in some patients, who are often retreated with a combination regimen called VOX/VEL/SOF, which is associated with very high rates of cure. However, VOX/VEL/SOF retreatment also fails in some patients. Herein, we analysed samples from patients in whom VOX/VEL/SOF retreatment failed and we assessed the efficacy of different rescue therapies, showing that rescue treatment is effective in most patients (81%).

来源:J Hepatol,查看原文。版权归原作者所有。

引用

  1. Dietz J, Di Maio VC, de Salazar A, et al. Failure on voxilaprevir, velpatasvir, sofosbuvir and efficacy of rescue therapy. J Hepatol. 2020. PMID: 33220331. doi:10.1016/j.jhep.2020.11.017

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。